Core Viewpoint - Huahai Pharmaceutical (600521.SH) has received approval from the National Medical Products Administration for the registration certificate of L-carnitine injection, which is used for complications arising from secondary carnitine deficiency in patients with chronic renal failure undergoing long-term hemodialysis [1] Group 1 - The L-carnitine injection is indicated for symptoms such as cardiomyopathy, skeletal myopathy, arrhythmia, hyperlipidemia, low blood pressure, and muscle cramps during dialysis [1] - The approval of L-carnitine injection enriches the company's product line and enhances its market competitiveness [1] - The product is classified as a chemical drug of category 4, which is considered equivalent to passing the consistency evaluation according to national policies [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年12月31日 | 狀態: | 新提交 | | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | 公司名稱: | CWT International Limited | | | | 呈交日期: | 2026年1月2日 | | | | I. 法定/註冊股本變動 不適用 | | | | FF301 第 1 頁 共 10 頁 v 1.1.1 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00521 | 說明 | | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | | 11,399,996,101 | | 0 | | 11,399,996,101 | ...

Group 1 - The core point of the article is that CWT INT'L has entered into a second sales agreement with GTS Shipping for the purchase of cathode copper, valued at up to $500 million (approximately HKD 39 million) [1] - The agreement is part of ongoing discussions for further collaboration in the commodity trading sector between CWT INT'L and GTS Shipping or any subsidiaries of HNA Technology [1] - The company believes that this second sales agreement will enhance its opportunities in commodity trading, potentially leading to increased gross profit and profit margins [1]

Core Viewpoint - CWT International (00521) has entered into a second sales agreement with GTS Shipping for the purchase of cathode copper, valued at up to $500 million (approximately HKD 39 million) [1] Group 1: Sales Agreement Details - The second sales agreement was signed on December 19, 2025, between MRI Trading, a wholly-owned subsidiary of CWT International, and GTS Shipping [1] - The agreement allows GTS Shipping to purchase additional cathode copper from MRI Trading [1] Group 2: Future Collaboration - Following the signing of both the first and second sales agreements, discussions will continue between the group and GTS Shipping (or any subsidiary of HNA Technology, 600751) regarding further cooperation in the commodity trading sector [1] - The company believes that the second sales agreement will enhance its opportunities in commodity trading [1] Group 3: Financial Implications - By continuing to engage with GTS Shipping as a client, the group expects to benefit from increased gross profit and gross margin in commodity trading [1]

Core Viewpoint - CWT INT'L (00521.HK) announced a new sales agreement for the purchase of cathode copper, indicating a strategic move to enhance its trading operations [1] Group 1: Company Announcement - The company’s indirect wholly-owned subsidiary, MRI Trading, has entered into a second sales agreement with GTS Shipping [1] - Under the agreement, GTS Shipping agrees to purchase additional cathode copper from MRI Trading [1] - The total contract value is capped at $5 million, which is approximately HKD 39 million [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 CWT INTERNATIONAL LIMITED （於香港註冊成立之有限公司） （股份代號：521） 關連交易 就商品貿易訂立第二份銷售合約 第二份銷售合約 茲提述前公告，內容有關訂立第一份銷售合約。 於 二 零 二 五 年 十 二 月 十 九 日（交 易 時 段 後），本 公 司 間 接 全 資 附 屬 公 司MRI Trading與GTS Shipping訂 立 第 二 份 銷 售 合 約，據 此，GTS Shipping同意向MRI Trading增購陰極銅。合約代價不得超逾5,000,000美 元（相 當 於 約 港 幣39,000,000 元）。於 訂 立 第 一 份 銷 售 合 約 及 第 二 份 銷 售 合 約 後，本 集 團 與 GTS Shipping（或 海航科技旗下任何附屬公司）將繼續商討及將考慮於商品貿易領域進一步合作。 – 1 – 第二份銷售合約 茲提述前公告，內容有關訂立第 ...

FF301 第 1 頁 共 10 頁 v 1.1.1 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年11月30日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | CWT International Limited | | | 呈交日期: | 2025年12月1日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00521 | 說明 | | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | | 11,399,996,101 | | 0 | | 11,399, ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: CWT International Limited 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 不適用 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00521 | 說明 | | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | | 11,399,996,101 | | 0 | | 11,399,996,101 | | 增加 / 減少 (-) | | | | | | | | | | 本月底結存 | | | | 11 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年9月30日 | 狀態: | 新提交 | | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | 公司名稱: | CWT International Limited | | | | 呈交日期: | 2025年10月2日 | | | | I. 法定/註冊股本變動 不適用 | | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00521 | 說明 | | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | | 11,399,996,101 | ...

CWT INTERNATIONAL LIMITED We hereby notify you that the English and Chinese versions of the Interim Report 2025 are now available on the Company's website at www.cwtinternational.com and Hong Kong Exchanges and Clearing Limited's website at www.hkexnews.hk (the "HKEX website"). You may visit the "Investor Relations" section on the home page of the Company's website or the HKEX website to view the Interim Report 2025. Pursuant to the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kon ...